Cargando…
Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance
Chemotherapy is routinely used in cancer treatment to eliminate primary and metastatic tumor cells. However, tumors often display or develop resistance to chemotherapy. Mechanisms of chemoresistance can be either tumor cell autonomous or mediated by the tumor surrounding non-malignant cells, also kn...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189297/ https://www.ncbi.nlm.nih.gov/pubmed/30356656 http://dx.doi.org/10.3389/fcell.2018.00131 |
_version_ | 1783363337749266432 |
---|---|
author | Ireland, Lucy V. Mielgo, Ainhoa |
author_facet | Ireland, Lucy V. Mielgo, Ainhoa |
author_sort | Ireland, Lucy V. |
collection | PubMed |
description | Chemotherapy is routinely used in cancer treatment to eliminate primary and metastatic tumor cells. However, tumors often display or develop resistance to chemotherapy. Mechanisms of chemoresistance can be either tumor cell autonomous or mediated by the tumor surrounding non-malignant cells, also known as stromal cells, which include fibroblasts, immune cells, and cells from the vasculature. Therapies targeting cancer cells have shown limited effectiveness in tumors characterized by a rich tumor stroma. Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant non-cancerous cells in the tumor stroma and have emerged as key players in cancer progression, metastasis and resistance to therapies. This review describes the recent advances in our understanding of how CAFs and TAMs confer chemoresistance to tumor cells and discusses the therapeutic opportunities of combining anti-tumor with anti-stromal therapies. The continued elucidation of the mechanisms by which TAMs and CAFs mediate resistance to therapies will allow the development of improved combination treatments for cancer patients. |
format | Online Article Text |
id | pubmed-6189297 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61892972018-10-23 Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance Ireland, Lucy V. Mielgo, Ainhoa Front Cell Dev Biol Physiology Chemotherapy is routinely used in cancer treatment to eliminate primary and metastatic tumor cells. However, tumors often display or develop resistance to chemotherapy. Mechanisms of chemoresistance can be either tumor cell autonomous or mediated by the tumor surrounding non-malignant cells, also known as stromal cells, which include fibroblasts, immune cells, and cells from the vasculature. Therapies targeting cancer cells have shown limited effectiveness in tumors characterized by a rich tumor stroma. Tumor-associated macrophages (TAMs) and cancer-associated fibroblasts (CAFs) are the most abundant non-cancerous cells in the tumor stroma and have emerged as key players in cancer progression, metastasis and resistance to therapies. This review describes the recent advances in our understanding of how CAFs and TAMs confer chemoresistance to tumor cells and discusses the therapeutic opportunities of combining anti-tumor with anti-stromal therapies. The continued elucidation of the mechanisms by which TAMs and CAFs mediate resistance to therapies will allow the development of improved combination treatments for cancer patients. Frontiers Media S.A. 2018-10-09 /pmc/articles/PMC6189297/ /pubmed/30356656 http://dx.doi.org/10.3389/fcell.2018.00131 Text en Copyright © 2018 Ireland and Mielgo. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology Ireland, Lucy V. Mielgo, Ainhoa Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
title | Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
title_full | Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
title_fullStr | Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
title_full_unstemmed | Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
title_short | Macrophages and Fibroblasts, Key Players in Cancer Chemoresistance |
title_sort | macrophages and fibroblasts, key players in cancer chemoresistance |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6189297/ https://www.ncbi.nlm.nih.gov/pubmed/30356656 http://dx.doi.org/10.3389/fcell.2018.00131 |
work_keys_str_mv | AT irelandlucyv macrophagesandfibroblastskeyplayersincancerchemoresistance AT mielgoainhoa macrophagesandfibroblastskeyplayersincancerchemoresistance |